A total of 15 samples (crude extracts and pure secondary metabolites) obtained from marine invertebrates collected from the offshore waters of British Columbia, Papua New Guinea, and Sri Lanka have previously been shown to exert cytotoxic activity in the in vitro L1210 leukemic bioassay. We screened these metabolites for in vitro cytotoxic activity against the drug-sensitive breasttumor cell lines MCF-7, T-47D, ZR-75-1, and MDA-MB-231; the multidrug-resistant and P-glycoprotein (Pgp)-positive breast-tumor cell lines MCF-7 Ad r and MDA-Alr; and normal and malignant human breast epithelial cells (ItBEC) in primary culture. Eight samples exhibited significant [drug concentration resulting in a 50% decrease in cell growth as compared with controls (EDso), <25 gg/ml] dose-dependent cytotoxicity against the drug-sensitive cell lines; the EDs0 values were as low as 0.004 gg/ml. Five of the eight samples exhibited significant cytotoxicity against the multidrug-resistant cell lines; the EDs0 values were as low as 0.0006 gg/ml. Incubation of MCF-7 Adr cells with varying concentrations of compounds in the presence of Adriamycin demonstrated that none of the compounds tested interfered with Pgp function. Results obtained using HBEC in primary culture showed a wide range of chemosensitivities for a given drug against tissue taken from different patients, demonstrating the uniqueness of the response of different individuals to chemotherapy.
Introduction
Currently, approximately 40 drugs are available for the treatment of cancer [24] . Combination chemotherapy for the treatment of breast cancer achieves response rates in the 50%-70% range, but complete remissions occur in only a small number of patients [15] . As a result, the development of new chemotherapeutic agents is critical.
Previous studies have shown that marine organisms represent a vast reservoir of new pharmacological agents with potentially unique modes of action [12, 20] . For example, the development of cytarabine, a widely used antileukemic chemotherapeutic agent, was based on leads provided by the isolation of 1-[3-arabinofuranosyl derivatives of uracil from the Caribbean sponge Cryptotethya crypta [1, 14, 27] . Didemnin-B, a metabolite of the tunicate Trididemnin solidum, has entered phase II human cancer trials [25] . The bryostatins, a family of metabolites isolated from the bryozoan Bugula neritina, will soon be undergoing clincial trials at the National Cancer Institute (NCI) [25] . Our laboratory has evaluated seven crude extracts and eight pure secondary metabolites derived from marine organisms for their potential in the treatment of breast cancer. We have previously shown that these compounds are cytotoxic in the in vitro L1210 leukemic bioassay.
Past drug-screening programs have relied on the in vivo L1210 and P388 leukemic bioassays as primary screens, and as a result, a large number of drugs effective in the treatment of leukemias have been developed. However, relatively few chugs effective against solid tumors have resulted from this approach [4] . Therefore, we initially screened these compounds against four drug-sensitive breast-tumor cell lines. In addition, these compounds were screened against the two multidrug-resistant (MDR) cell lines MCF-7 Adr and MDA-Alr [11, 23] . These MDR cell lines are resistant to a number of drugs that are structurally and functionally unrelated. A major mechanism of MDR is associated with increased levels of the plasma membrane protein P-glycoprotein (Pgp) [13, 26] . Pgp functions as a pump that actively transports drugs out of the cell, thus resulting in a net lower intracellular drug concentration. Both the MCF-7 Ad r and the MDA-A1 r cell lines exhibit Pgp amplification (60-fold and 10-to 30-fold, respectively), increased Pgp mRNA expression, and decreased Adriamycin uptake [11, 23] .
The MDR cell lines were included in the present drugscreening protocol to identify new drugs that might circumvent the MDR phenotype. Unfortunately, cell lines represent a ve12r homogeneous and highly selected population of cells and thus do not represent the heterogeneous population seen in naturally occurring tumors. Therefore, we tested the cytotoxicity of these compounds against a panel of cell lines. In addition, we assayed two of the most cytotoxic compounds from the cell-line screenings against normal and malignant human breast epithelial cells (HBEC) in primary culture, which more closely resemble the counterpart cells in vivo. Normal HBEC were included in the screening protocol to detect tumor-specific agents. It has been shown that the selective activity of a chemotherapeutic drug against cancer cells in vitro relative to normal cells does result in antitumor activity in vivo [21] .
Materials and methods
Isolation and purification of compounds. The procedures used for the isolation and purification of the geodiamolides [6] , bromotopsentin [ 18] , xestospongin E [16] , bastidin-4 [17] , imbricatine [2] , chromodorolide A [7] , jaspamide [5] , glaciasterol A [22] , and the Garvea extract [10] have previously been described. The crude extracts of the other organisms were prepared by homogenizing the organisms in methanol, filtering, and evaporating the methanol in vacuo. Cultures were maintained in a humidified atmosphere consisting of 5% CO2 and 95% air at 37 ~ C and were subcultured weekly by treatment with saline-trypsin-versene (MCF-7, T-47D, ZR-75-1, MDA-MB-231, and MCF-7 Ad r) or with calcium and magnesium-free phosphatebuffered saline (PBS) supplemented with 1 mM ethylenediaminetetraacetic acid (EDTA; MDA-Alr). At the time of the experiment the cells were resuspended, and viable cells, determined by trypan-blue exclusion and counted on a hemacytometer, were seeded at 4 x 103 cells/well onto 96-well microtiter plates (Falcon, Becton Dickinson Co., N. J.) in 100 gl FI2/DME/I-I supplemented with either 5% FBS and 5 gg insulin/m! (MCF-7, T-47D, ZR-75-1, and MCF-7 Ad9 or 10% FBS (MDA-MB-231 and MDA-A lr).
Nornaal tissue cells obtained from breast reductions and malignant tissue obtained from biopsies and mastectomies were prepared as described elsewhere [9] . Tissues were minced and dissociated in F12/DME/H supplemented with 2% bovine serum albumin (Gibco), 5 gg insulin/ml, 300 U collagenase/ml, and 100 U hyaluronidase/ml (Sigma) at 37~ for 18 h. The epithelial cell pellet was collected by centrifuging the cell suspension at 80 g for 4 min. The pellet was washed twice with F12/DME/H and viable cells were counted. Cells were resuspended and seeded at 1 x 104 cells/well onto collagen-coated 96-well microtiter plates in 100 gl F12/DME/H, 5 gg insulin/ml and 5% patients' sera.
Serum samples were collected in the mornings from patients who had fasted over the previous 8 -12 h. Blood was received in nonheparinized tubes, incubated for 30 rain at 37~ and centrifuged at 100 g, and the serum was collected. If not used immediately, the serum was stored at -20~
Compound-testing protocol. On day 0, the cells were seeded onto the microtiter plates as described above. After 24 h, the medium was removed and 100 gl fresh medium containing serial dilutions of the agents to be tested was added to the wells. Cultures were incubated with the drugs for 48 h. The cells were then washed and cultured in drug-free medium for 48 h. A 48-h drug-incubation period was selected to ensure that all ceils passed through at least one cell cycle, thus allowing phase-specific and cell-cycle-specific agents to exert their effects. The cell-cycle times of MCF-7, T-47D, ZR-75-1, MDA-MB-231, MCF-7 Ad r, and MDA-A1 r cells are 30, 22, 44, 21, 23, and 18 h, respectively. A 48~h drug recovery period was selected to ensure that cytostatic agents could be distinguished from cytotoxic agents. After the recovery period, the cells were quantified by the tetrazolinm-dye reduction (MTT) assay [3, 19] .
In some experiments performed to detect agents that might circumvent the MDR phenotype, MCF-7 Ad r cells were incubated in the concentration of Adriamycin that results in a 50% decrease in cell growth relative to controls for this line (EDs0, 5 gg/ml) as well as in different concentrations of the drug to be tested during the incubation period.
MTT assay. The medium was removed and 100 gl MTT (1 mg/ml, Sigma) dissolved in phenol-red-free F12/DME/H (Sigma) was added to each well. Following a 5-h incubation period at 37 ~ C, 100 g120% formol in saline was added to each well and left for 30 rain at room temperature to fix the cells to the plate. The formol-saline-MTT solution was then gently removed with a multichannel pipette (Titertek/ICN Flow, Costa Mesa, Calif.), and 100 btI isopropanot was added to each well to dissolve the formazan crystals. After 1 h, the plates were read on a 96-well microplate reader (model EL 311, Biotek Instruments Inc., Winooski, Vermont) at 540 nm. Absorbance values were converted to cell numbers via standard curves specific for each cell line. Cytotoxicity was determined by comparing drug-treated cultures with control cultures (which are assigned a value of 100%). The EDs0 value was then determined from the dose-response curve. Figure 1 illustrates the wide range of chemical structures of all of the pure samples tested in our in vitro screening protocol. Table 1 summarizes the EDs0 values obtained for compounds screened against the MCF-7, T-47D, ZR-75-1, and MDA-MB-231 cell lines. Of the 15 samples screened, 8 demonstrated significant cytotoxicity (EDs0, <25 gg/ml) against either the MCF-7 or the T-47D cell line. Only these 8 samples were screened against ZR-75-1 and MDA-MB-231 cells; all 8 compounds were significantly cytotoxic against the former cell line, whereas 6 were significantly cytotoxic against the latter.
Results

Compounds screened against drug-sensitive cell lines
The EDs0 values for Adriamycin were determined in all of these cell lines to provide a standard with which the samples could be compared. The EDs0 values recorded for two pure samples, the geodiamolides and jaspamide, were comparable with or lower than those noted for Adriamycin. The values obtained for another sample, QCI-32, which is a crude extract, were 12-, 1. Values recorded for the five remaining compounds that exhibited significant cytotoxicity ranged from 0.58 to 33 gg/ml and were at least 9-fold those found for Adriamycin. line. MCF-7 Adr cells were 50 times more resistant to Adriamycin than was the parent MCF-7 cell line, whereas MDA-A1 r cells were 184 times more resistant than was the parent line MDA-MB-231. Table 2 also compares the ED5o values found for compounds screened against the MDR ceil lines MCF-7 Ad r and MDA-A1 r with those obtained using the drug-sensitive parent cell lines (EDs0 drug-resistant/EDs0 drug-sensitive).
Compounds screened against drug-resistant cell lines
Compounds screened against MCF-7 Ad r cells in the presence of Adriamycin
To determine whether compounds whose ED50 ratios were less than or equal to 1 might circumvent the MDR phenotype by interfering with Pgp, MCF-7 Ad r cells were incubated in the presence of the EDs0 concentration (5 gg/ml) of Adriamycin and in varying concentrations of test compounds. Additive cell cytotoxicity was observed between Adriamycin and all compounds tested (results not shown). However, no synergy was observed between any of the samples and Adriamycin, suggesting that these compounds do not interfere with Pgp function. Table 3 summarizes the cytotoxicities of the geodiamolides and jaspamide as tested against malignant and normal HBEC in primary culture. No significant trend indicating tumor specificity was observed for either of these agents. However, broad variation was seen in the cytotoxicity of a given agent for different tissue samples: the EDs0 values recorded for the geodiamolides ranged from 0.018 to 5.5 gg/ml and from 0.21 to >10 gg/ml in malignant and normal tissue, respectively, whereas the corresponding values determined for jaspamide ranged from 0.0005 to 3.8 gg/ml and from <0.05 to 0.5 gg/ml. Adriamycin EDs0 values were included for reference in cases in which sufficient tissue was available.
Compounds screened against normal and malignant HBEC in primary culture
Discussion
Past drug-screening programs have illustrated that the incorporation of solid tumors into a drug-screening protocol is essential, since agents that are effective in treating leukemias are not necessarily effective against solid tumors [4] . The crude extracts and pure metabolites evaluated herein had previously been screened and found to be cytotoxic in vitro in the leukemic L1210 bioassay. In the present study, mammary carcinoma was used as a solid-tumor model. Breast-cancer cell lines were selected for initial screening because the cells are plentiful and easy to grow. However, cell lines result from cell selection and the populations are very homogeneous in their characteristics. Therefore, we used four drug-sensitive and two drugresistant breast-tumor cell lines to represent the heterogeneity seen in naturally occurring breast tumors. In addition, primary cultures of epithelial cells from malignant breast tissue were incorporated into the screening protocol because they more closely resemble the counterpart cells in vivo. Epithelial cells from normal tissue were also included to determine the tumor specificity of these agents. As our results illustrate, there was broad variation in the biological activity of cytotoxic compounds tested on different cell lines and on different primary cultures.
Of the 15 compounds tested against the drug-sensitive cell lines MCF-7 and T-47D, 8 demonstrated significant activity. Agents with an ED50 value of up to 25 gg/ml were selected for further testing against the ZR-75-1 and MDA-MB-231 cell lines and the drug-resistant cell lines. We selected 25 gg/ml as our cutoff value because some of the compounds tested were crude extracts, and an excessively low cutoff point might have resulted in the exclusion of potentially toxic compounds from further testing. In addition, some of the compounds with ED50 values of around 25 gg/ml exhibited low in vivo host toxicity (unpublished results).
The geodiamolides (a mixture of two cyclodepsipeptides that are identical except that one is brominated and the other is iodinated) and jaspamide are very promising compounds, since they exhibited cytotoxicity comparable with that of Adriamycin when tested against the drug-sensitive cell lines and were several orders of magnitude more cytotoxic than Adriamycin when screened against the MDR cell lines. The observation that compounds such as the geodiamolides were much less cytotoxic against MCF-7 Ad r cells as compared with the parent line MCF-7, whereas they were more cytotoxic against MDA-Alr cells than against the parent line MDA-MB-231, suggests either that cellular mechanisms in the MDA-Alr cells may enable the drugs to overcome the effects of Pgp overexpression or that these drugs are simply not affected by this efflux pump. Our failure to observe synergy between any of the samples and Adriamycin indicates that these drugs do not interfere with Pgp function. These compounds were also very cytotoxic against some of the malignant and normal HBEC in primary culture. The four crude extracts PNG-31A, BC-3, QCI-32, and PNG-137A also warrant further investigation since they demonstrated significant cytotoxicity in the preliminary cell-line screens; their full potential may not be realized until the pure active metabolites have been isolated.
For the drugs that demonstrated in vitro activity, we will determine the therapeutic index (median lethal dose/median effective dose) using mice bearing the transplantable Shionogi mammary carcinoma from our colony [7] . As the structures of the pure samples illustrate (Fig. 1) , marine organisms represent a vast reservoir of new and interesting chemical families that potentially provide novel modes of action, better therapeutic indices, and fewer side effects and are effective against currently untreatable solid tumors.
